MKI67 and non-small cell lung carcinoma: Using datasets from phase 3 randomized controlled trials of anti-PD-L1 immunotherapy in NSCLC,33 we found that anti-PD-L1 immunotherapy conferred survival benefits for patients with a low Ki67+ Treg score, but not for those with a high score (Supplementary Fig. 13a).